Figure legends
  1. Patient enrollment. Based on this, a total of 969 COVID-19 patients were evaluated for eligibility. Of those, 194 participants were included in the study and were divided into two groups, favipiravir (n=101) and HQ (n=93). HQ, hydroxychloroquine; ECG,electrocardiography.
  2. Comparison of post-treatment data of the two groups. The post-treatment proportion of arrhythmic events (Panel A ) (13.9% vs. 19.8%) and sinus bradycardia (Panel B ) (3.2% vs. 13.9%) between the groups. The comparison of ΔHR (Panel C ) (12 [IQR:-6—70] vs. 5 [IQR:-8—41]) and ΔQTc (Panel D ) (11 [IQR:-9—57] vs. 12 [IQR:-7—103]) between the groups. HR, heart rate; HQ,hydroxychloroquine; QTc, corrected QT; ΔHR, the initial and final heart rate difference; ΔQTc, the final and initial QTc interval difference.
  3. HR (Panel A, Panel B ) and QTc interval (Panel C, Panel D ) changes in patients pre/post-treatment. HR, heart rate; HQ, hydroxychloroquine; QTc, corrected QT.